Agnes Zoller, PhD’s Post

Exciting insights from HSBC's latest report on the 2023 private markets landscape and some predictions for 2024! 🚀 Key takeaways worth noting: 📊 First Financing Valuations: In 2023, median valuations soared to $21M, a 24% YoY increase. Notably, clinical-stage entities and AI/techbio companies dominated the high-valuation spectrum, revealing investor preferences. 🌐 Biopharma VC Activity: Despite a 23% dip in overall investment activity, the latter half of 2023 saw a resurgence in mega-financings, with 16 deals surpassing $200M. Clinical data remained a focal point, but preclinical ventures still attracted significant attention. 🎯 Investment by Indication: Nuanced shifts in investment patterns emerged, with neuro indications maintaining consistency and oncology experiencing a 27% downturn. Clinical-stage ventures took center stage again, especially in cardiovascular and AI. 💼 Insider Rounds Surge: With the IPO window largely closed, insider financings surged in 2023, accounting for 40-50% of rounds. This is anticipated to change in 2024 as public markets are expected to open. 📈 Step-Up Analysis: Contrary to expectations, the median step-up factor was 1.4x across all stages, showcasing companies' preference to avoid down rounds. Series A and Series B step-ups revealed a focus on clinical data and substantial advancements. 💰 Largest Post-Money Valuations: Corporate VCs led the majority of mega rounds in H2 2023, extending runways for ventures. Traditional crossover venture capital made a notable comeback, indicating a return to conventional funding sources. 🤝 Private M&A: Private M&A activity in 2023 was limited, with only six deals, three exceeding $1B. The obesity space dominated, showcasing the industry's focus on high-value assets. 💡 Techbio Deals and Step-Ups: Techbio deal sizes varied, with median first financing at $5.2M. Pharma and tech giants actively participated in deal-making, emphasizing AI for pre-clinical discovery. Step-ups across categories highlighted the sector's resilience, with Infrastructure and Platform commanding a higher step-up at 1.6x. If you haven't already, I encourage you to check out the full report below. #Biotech #InvestmentTrends #TechBio #PrivateMarkets

Kisaco Research Women's Health Innovation Summit USA Investment Strategies for Long Term Success Moderated by Mimi Ghosh ➡️ Bank of America Jin Lee ➡️ Oxford Angel Fund 📍Focus on how your solution will help the situation secure reimbursement and/or cost savings. 📍About 70-80% of B2C companies that start off; end up going B2B2C. 📍Follow the money and illustrate that your solution will provider a longer term solution for the pharma side and the payer side is open to less risk (cost). 📍Physician burnout and hiring are the two key factors driving purchase decisions on the health system side -> can you help that!? 📍 Anna Mason ➡️ Ingeborg Investments 📍Often the conversation centers around the incumbent's speed to market vs. the start-up... a hack is to find your distribution power. 📍Cash is like carbs and efficiency is like protein -> deals are getting done and it's more of a silver lining for operators to lean into... be efficient! 📍Venture investments often come down to these three factors: access, context & judgement. Have an open mind and healthy dose of skepticism. 📍We're in an industry of #BatSignals -> authentically connect your brand to what you stand for. This was key for her funds: "We invest in innovation for the full female experience." 📍It's always easiest if you begin with the end in mind. Elizabeth Bailey ➡️ RH Capital 📍One of the bright spots she has seen is seeing strategic investors step up in much earlier stages w/in Women's Health. This is great because theirs value in bringing in a strategic partner when when they don't have the (costly) infrastructure. 📍it's a mistake to give preferential terms up front and look to have multiple strategics in play. The space is newer, so be creative in putting together a deal. 📍Investments can go south if investors and management pull in different directions due to a lack in transparency. Mgmt needs to talk about struggles. CC Lucy Bale, Aoife McGrath (Eefa), Rebecca Baldwin #WHIS #VC #VentureCapital

Deloitte has some insights into how early-stage medtech investors can attract investors.

Startup Central | El Toro Finseve: Anti-ageing tech gaining momentum Kapil Khandelwal KK explains 'happiness medicines' shaping healthcare demand, mental well-being and how the co plans to revolutionize the health sector Avanne Dubash Kapil Khandelwal KK

💰 Investing in emerging #biotech and #healthcare companies is a unique venture that requires knowledge and understanding of both the technology and the team behind the science. Here, Jason Novak and Nathanael Green, PhD of Norton Rose Fulbright, alongside Milad Alucozai address themes for what makes a startup-investor team productive and how these themes lead to valuable companies. These themes should be considered by #investors and #founders alike (and their #legalcounsel) to consider each role in the bigger picture. This helps both sides’ understanding of what their counterpart considers and how they can shape their strategy to maximise the team’s output. Here’s the link to the full article 🔗 https://lnkd.in/eMbScPSr #digitalhealth #digitalhealthinnovation

Women’s health is underfunded, underserved, and understudied, and the consequences are dire. I’m thrilled to finally release our first-ever Innovation in Women’s Health report, which covers venture fundraising, investment, and exits in the women’s health space. We define women’s health as healthtech, biopharma, diagnostics/tools and medical device companies that address underserved care needs for women and individuals with female biologies. The #SVBHealthcare team hosted a webinar with Somer Baburek, MBA @ Hera Biotech and Naseem Sayani (she/her) @ Emmeline Ventures to cover the report’s key findings. You can catch the replay here: https://lnkd.in/g2us5tra Some key takeaways: - Life sciences are underrepresented in women’s health funding, comprising 66% of all healthcare deals, but only 46% of women’s health deals. However, with the increasing clinical research and availability of outcomes data, science-based solutions should experience a surge. - Women’s health venture activity has flourished the past five years, growing 314% since 2018, compared to a 28% increase in overall healthcare investments. 2023 is on pace to become a top three funding year for the space. - Investors are warming up to the untapped opportunity to serve the vast spectrum of women’s health needs beyond reproduction and across their full life courses. Investments in non-reproductive startups reached $435M in Q3 2023 – a single quarter record. Delphine O'Rourke Deena Shakir Frederique Dame Jessica Karr Jackie Spencer Jennifer Friel Goldstein Nina Kandilian Pooja Majmudar, PhD Julie Betts Ebert Amar Sawhney Alice Zheng Shailja Dixit Andrea Ashford-Hicks Shilpa Patel Kate Wallis Lux Capital GV (Google Ventures) Point32Health Coyote Ventures RH Capital Longitude Capital Annie Scolamieri Wyss Institute at Harvard University Flare Capital Partners Sasha Kelemen Maven Clinic Midi Health Ariana Ognibene Health In Her HUE Jim O'Connor Visana Health Mae Kindbody Cayuga Biotech Curio Digital Therapeutics Inc.

Thank you Raysa Bousleiman and #SVBHealthcare team for publishing this very insightful, Innovation in Women's Health report. On #womenshealth as an investment category -- its growth so far and the untapped potential that's becoming more recognized among generalist investors: Appreciate the depth and pragmatic and poignant views on expressed by Somer Baburek, MBA Hera Biotech Naseem Sayani (she/her) Emmeline Ventures and Raysa Bousleiman in the lively discussion moderated by Lydia Ramsey Pflanzer in this webinar: https://lnkd.in/g2us5tra Whether you are an investor, provider, healthcare technologist / entrepreneur, or a traditional healthcare company, there is a lot to learn! Here are some quotes that say a ton: Somer Baburek, MBA on the importance of engaging providers: "...you can't give birth in the metaverse..." Naseem Sayani (she/her) on the TAM of women's health being in the Trillions: "...women's health address 50% of the population that's birthing 100% of the future...menopause for 40-50% of her life...purchase a subscription product every month for 40-50% of her life...in 2022, the women's health as a category was over a trillion dollars in value [whereas] all of VC deployed $455B across every sector...less than 2% of that went to women's health...people are finally understanding that this is the arbitrage opportunity that we've been looking for..." The last 7 min. of the webinar is a great discussion about what makes a sustainable innovation in women's health. This is a topic near and dear to Univfy's core foundation and mission: The intersection of women's health, #AI and basic science is essential in building sustainable innovations in women's health. That is the vision of our founding team which has now been translated to a commercialized #AIML platform serving the fertility space. We continue to build on that to support providers in delivering better and more personalized fertility care to help more people build their families. I agree wholeheartedly with the panel that AI platforms must address the needs of diverse patients and Univfy has that as our North start from day 1 -- we have built validated, no-code AIML implementation that is relevant to local providers and patients and that is scalable globally to diverse socio-economic environments and cultures.

As one of the busiest weeks for the healthtech industry @ HLTH comes to a close, I'd like to share Silicon Valley Bank's Future of Healthtech 2023 report I had the pleasure of putting together with my incredible colleagues Jackie Spencer, Julie Betts Ebert, and Nina Kandilian. It provides a comprehensive overview of the venture investment, fundraising, M&A, public performance, value-based care, and strategic player trends in the #healthtech space. Some key takeaways: • Investments approach solid ground: $8B in healthtech investment this year, with the last 3 quarters remaining relatively stable following the steep drops we saw in 2022. • Valuation haircuts: There's been a wave of down and flat rounds, which are likely underreported in the data. Many later-stage companies are revising growth projections and cutting costs to avoid fundraising this year to escape difficult valuation conversations.  • Mega-deal volume down significantly, but value-based care was a bright spot. Half this years mega deals focused on VBC delivery or enablement: Carbon Health, Monogram Health, Strive Health, Aledade, Inc., Vytalize Health.   • #valuebasedcare isn't going anywhere but significant challenges persist, with different players taking on varying levels of risk. We've seen a burgeoning of specialty care value-based care players (and investment), such as Thyme Care, Mindoula, and Cricket Health. • Strategic players: retail and tech giants CVS Health, Walgreens and Amazon are increasingly pushing into healthcare by vertically integrating different parts of the healthcare journey. Payers Cigna Healthcare, UnitedHealthcare/Optum, and Elevance Health are investing in/partnering with smaller, more nimble healthtech companies to get a seat at the table to see what’s most effective while reducing risk. While the near-term outlook remains choppy, our belief is that this market correction has lead to an appropriate right-sizing of the market which will lead to a more sustainable future.

Unveiling the Future of Health Tech: Insights from Angel Investor Chandran Krishnan. In today's fast-paced world, the intersection of healthcare and technology is reshaping our future with unmatched dynamism. At the forefront of this transformative healthcare revolution are angel investors, who are playing a pivotal role in defining the industry's evolution. Join us as we embark on a deep dive into the intricate ecosystem of Health Tech innovation. In our latest article, Chandran K, our Principal Advisor and MD & CEO of Campus Angels Network, a seasoned angel investor, shares invaluable insights into the current trends and emerging opportunities that characterize this dynamic landscape. Whether you're an investor seeking to navigate this ever-changing terrain or an entrepreneur with a vision to revolutionize healthcare, this article serves as a comprehensive guide. It's your key to understanding and thriving in the Health Tech space. Discover the trends that are reshaping healthcare, uncover the insights that matter, and embrace the transformative potential of Health Tech with us. The future of healthcare innovation is here, and we are excited to explore it with you! #HealthTech #AngelInvesting #Innovation #Insights #FutureOfHealthcare #SSNiFound #TNIncubators

Part 4 of 5, LSI Panel Insights Today’s topic: Medtech Investment Activity In this clip, Jonathan Norris, Managing Director at HSBC Innovation Banking, discussed how Medtech investment activity continues to show resilience when compared to other sectors. In 2023, Medtech deal activity declined only 19% from 2022 levels, and impressively, it’s up 4% compared to 2020. This steadiness has been driven primarily by later-stage commercialization and pivotal trial funding. Looking ahead to 2024, he anticipates a slowdown, largely due to the prevalence of insider rounds in 2023. This trend suggests fewer but more consolidated new rounds throughout this year. Tune in the rest of the week as we cover the harsh realities, insights, market data, optimism, and authenticity discussed throughout this panel. Watch the full panel featuring Jonathan Norris, Anita Watkins, Sean J. Cheng, Martin Omid A., and Daniel Hawkins. Available on our website and YouTube channel titled “Harsh Realities in Building and Financing Medtech Ventures”.